Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review

Soft tissue sarcomas harboring EWSR1::CREM fusion are rare and challenging to treat. Pazopanib, a multi-tyrosine kinase inhibitor, is FDA-approved for advanced soft tissue sarcomas, but predictive biomarkers for its efficacy remain unidentified. We conducted a study on > 240,000 neoplasms submitt...

Descripción completa

Detalles Bibliográficos
Autores principales: Campoverde, Leticia, Camacho, Felipe, Alessandrino, Francesco, Evans, Mark G., Elliot, Andrew, Rosenberg, Andrew, Trent, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565213/
https://www.ncbi.nlm.nih.gov/pubmed/37829338
http://dx.doi.org/10.3389/fonc.2023.1215003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565213/
https://www.ncbi.nlm.nih.gov/pubmed/37829338
http://dx.doi.org/10.3389/fonc.2023.1215003

Ejemplares similares